Table V.
Clinical trial on fotemustine as second-line chemotherapy in recurrence MGs after temozolomide failure.
| Authors, year | No of patients | Histotype | Recurrence | Schedule | mPFS, months | PFS6, % | mOS, months | DCR, % | Grade 3–4 toxicity | (Refs.) |
|---|---|---|---|---|---|---|---|---|---|---|
| Scoccianti et al, 2008 | 27 | GBM | II | Standard | 5.7 | 48.15 | 9.1 | 48.1 | 14.8% | (13) |
| Fabrini et al, 2009 | 50 | MGs | II | Standard | 6.1 | 51.5 | 8.1 | 62.0 | 14% | (14) |
| Brandes et al, 2009 | 43 | GBM | II | Standard | 1.7 | 20.9 | 6.0 | 42.5 | 50% | (15) |
| Fabi et al, 2009 | 40 | MGs | II and III | Range of doses | 4.0 | 27.0 | 30.0 | 47.5 | 40% higher dose (standard schedule) | (22) |
| Fabi et al, 2010 | 40 | MGs | II and III | Low dose | 3.0 | 21.0 | 6.0 | 52.5 | 27.5% | (6) |
| Addeo et al, 2011 | 40 | GBM | II | Fractionated | 6.7 | 61.0 | 11.1 | 65.0 | 12.5% induction phase 17.7% maintenance phase | (16) |
| Gaviani et al, 2013 | 20 | MGs | II and III | Fractionated | 3.7 | 38.2 | 6.9 | NA | 19.2% | (15) |
| Present study | 40 | MGs | II | Fractionated | 4.0 | 33.0 | 9.0 | 60.0 | 24.3% |
MGs, malignant gliomas; GBM, glioblastoma mutiforme; mPFS, median progression-free survival; mPFS6, median PFS at 6 months; mOS, median overall survival; DCR, disease control rate; NA, not available.